Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
NeXT Dx combines whole exome (DNA) and whole transcriptome (RNA) sequencing in a paired tumor-normal assay to uncover deeper insights for cancer care. By detecting fusions from RNA, providing exome-wide TMB, and reducing false-positives, the NeXT Dx test delivers more accurate results and improves chances of finding an effective therapy or clinical trial.
RNA detects 15%–30% more fusions than DNA1,2
Michuda J et al. Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 3077.
Benayed R et al. Clin Cancer Res 2019, 25(15) 4712-22.
Deeper coverage with 200M total reads3
Internal data on file.
Eliminates false positives attributable to germline.
25%–30% fewer false positives than Tumor-Only testing3
Exome-wide TMB provides greater accuracy than panel-based testing4,5
21%–44% of patients are misclassified as TMB-high with Tumor-Only testing6
Nassar AH et al. Cancer Cell. 2022;40(10):1161-1172.e5.
Follow our simple, four-step process.
1
Request the NeXT Dx test kit through our Clinical Portal or reach out to clientservices@personalis.com.
2
We’ll need samples of your patient’s tumor, and blood or saliva.
3
Your kit includes a convenient, prepaid return label.
4
Results will be available in about 2 weeks (after sample receipt) to allow you to discuss treatment options with your patient.
Suitable for any patient with a solid tumor, NeXT Dx is a high-performance comprehensive genomic profiling (CGP) test based on augmented whole exome and transcriptome sequencing.
It works by using next-generation sequencing (NGS) with deep coverage to report small nucleotide variants (SNVs), insertions and deletions (indels), copy number alterations (CNAs), fusions from RNA, MSI from 117 loci, exome-wide TMB, and HLA-typing. Variants in certain cancer-related genes that may be germline in origin are reported as incidental findings to reduce false-positives. In addition, variants in genes involved in homologous recombination repair (HRR) are highlighted when identified. A list of the 401 cancer-associated genes reported by the NeXT Dx test may be found here.
NeXT Dx is a next-generation sequencing (NGS) based laboratory developed test (LDT) for cancer patients with solid tumors. NeXT Dx analyzes the whole exome to report small nucleotide variants (SNVs), small insertions and deletions (indels), copy number alterations (CNAs), and gene fusions in select cancer-related genes as well as MSI and exome-wide “true” TMB. Alterations detected by NeXT Dx are reported with associated therapeutics or matched clinical trials. Genomic findings are not prescriptive or conclusive for labeled use of any specific therapeutic product. Tests may result in no reportable alterations and/or no associated therapeutics or clinical trials. A negative result does not rule out the presence of an alteration. NeXT Dx is performed in the CLIA/CAP accredited Personalis Clinical Laboratory. NeXT Dx was developed and performance characteristics determined by the Personalis Clinical Laboratory. NeXT Dx has not been cleared or approved by the United States Food and Drug Administration (FDA). The Personalis Clinical Laboratory is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing.
Clinical samples submitted in the form of isolated or extracted nucleic acids will only be accepted if the isolation of nucleic acids occurs in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.
